# PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium

- Link: https://www.thailand-business-news.com/pr-news/paq-therapeutics-to-present-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-in-late-breaking-oral-presentation-at-the-2026-eortc-nci-aacr-symposium
- Published: 2026-11-03T19:00:00+07:00
- Author: PR Newswire

|   |

_Presentation to highlight the initial safety profile and antitumor activity of 
PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-
targeted therapy_

BURLINGTON, Mass., Nov. 3, 2026 /PRNewswire/ — PAQ Therapeutics, a clinical-stage
biotechnology company developing targeted protein degraders for KRAS-driven cancers
with significant unmet medical need, today announced that first clinical data for
PT0253, its selective KRAS G12D degrader, will be presented in a late-breaking oral
presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics (ENA 2026), being held November 18–20 in Barcelona, Spain. The presentation
will report findings from the company’s ongoing Phase 1 trial in patients with advanced
solid tumors. PAQ will also present a poster describing the preclinical profile 
of PT0253.

**ENA 2026 Presentations**

**Late-Breaking Oral Presentation**

**Abstract 6LBA: **PT0253, a selective KRAS G12D degrader, shows a differentiated
safety profile and antitumor activity, including after prior (K)RAS therapy, in 
advanced solid tumors
**Session: **Plenary Session 6 – Proffered Papers: Advances
in Targeting RAS**Date/Time: **Friday, November 20, 2026, 12:36–12:44 p.m. CET**
Authors: **Leontios Pappas, William B. McKean, Alexander I. Spira (Presenting Author),
Drew W. Rasco, Ildefonso I. Rodriguez-Rivera, Anthony Tolcher, Do-Youn Oh, Hye Jin
Choi, Jin Won Kim, Joon Oh Park, Heung-Moon Chang, Hong Jae Chon, Huaixiang Hao,
Lokesh Gakhar, Joseph Donahue, Adam Shilling, Eric Rubin, Nan Ji, Andrew P. Krivoshik

**Poster Presentation**

**Abstract 320: **PT0253 is a potent and selective KRAS G12D degrader for treatment
of cancers
**Session: **New Drugs**Date: **Friday, November 20, 2026**Poster Board:**
PB-112**Authors: **Huaixiang Hao, Pengrong Yan, Yuxin Wang, Fei Feng, Lokesh Gakhar,
Ning Yin, Hui Qiu, Ruoxi Lan, Nan Ji

**About PAQ Therapeutics**

PAQ Therapeutics is a clinical-stage biotechnology company focused on advancing 
targeted protein degradation to address the unmet medical needs of patients with
KRAS-driven cancers. Its clinical pipeline comprises PT0253, a selective KRAS G12D
degrader, and PT0511, a pan-KRAS degrader, both in Phase 1 development for patients
with advanced solid tumors. The company is based in Burlington, Massachusetts.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium ](http://www.prnasia.com/story/archive/5086231_CN86231_0?rand=184833)